Lixin Rui

3.4k total citations · 1 hit paper
37 papers, 1.9k citations indexed

About

Lixin Rui is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Lixin Rui has authored 37 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Molecular Biology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Lixin Rui's work include Lymphoma Diagnosis and Treatment (16 papers), Cancer-related gene regulation (7 papers) and CAR-T cell therapy research (6 papers). Lixin Rui is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Cancer-related gene regulation (7 papers) and CAR-T cell therapy research (6 papers). Lixin Rui collaborates with scholars based in United States, Australia and United Kingdom. Lixin Rui's co-authors include Christopher C. Goodnow, Carola G. Vinuesa, Fen Zhu, Julie Blasioli, Louis M. Staudt, Matthew Cook, Belinda Whittle, John I. Bell, Constanza Angelucci and Heather Domaschenz and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Lixin Rui

35 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity

2005 690 citations Carola G. Vinuesa, Matthew Cook et al. Nature profile →

Peers

Countries citing papers authored by Lixin Rui

Since Specialization

Citations

This map shows the geographic impact of Lixin Rui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lixin Rui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lixin Rui more than expected).

Fields of papers citing papers by Lixin Rui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lixin Rui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lixin Rui. The network helps show where Lixin Rui may publish in the future.

Co-authorship network of co-authors of Lixin Rui

This figure shows the co-authorship network connecting the top 25 collaborators of Lixin Rui. A scholar is included among the top collaborators of Lixin Rui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lixin Rui. Lixin Rui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Preclinical Evaluation of [⁶⁴Cu]Cu-NOTA-ABDB6: A CD70 and Albumin Dual-Binding Tracer with Improved Pharmacokinetics 2025 ·Journal of Nuclear Medicine ·Xiaoyan Li, You Zhang, Jason C. Mixdorf, (unknown), (unknown), Jonathan W. Engle, (unknown), Shannon C. Kenney, Lixin Rui, Weijun Wei, Weibo Cai	1
2	Analysis of Regulatory Botanical Submission Profile for Cancer Management from the U.S. FDA Perspectives 2025 ·Therapeutic Innovation & Regulatory Science ·(unknown), Daniel Lee, Lixin Rui, (unknown), M. Scott Furness, (unknown)	1
3	Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations 2023 ·Blood Cancer Journal ·Yuxuan Che, Yang Liu, Yixin Yao, Holly A. Hill, Yijing Li, Qingsong Cai, Fangfang Yan, Preetesh Jain, Wei Wang, Lixin Rui, Michael Wang	13
4	Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax 2023 ·Haematologica ·(unknown), Jennifer L. Crombie, Wei Ni, (unknown), Swati Garg, (unknown), Stephen Jun Fei Chong, (unknown), Lixin Rui, James D. Griffin, Matthew S. Davids	7
5	EGR1 Addiction in Diffuse Large B-cell Lymphoma 2021 ·Molecular Cancer Research ·(unknown), Li Lü, Nguyet M. Hoang, Fen Zhu, Paul D. Bates, Anusara Daenthanasanmak, Shanxiang Zhang, David T. Yang, (unknown), (unknown), Yangguang Li, (unknown), (unknown), (unknown), (unknown), Thomas A. Waldmann, Christian M. Capitini, Lixin Rui	10
6	Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice 2021 ·PLoS ONE ·Etienne Masle‐Farquhar, Amanda J. Russell, Yangguang Li, Fen Zhu, Lixin Rui, Robert Brink, Christopher C. Goodnow	3
7	DNA methyltransferases in hematological malignancies 2020 ·Journal of genetics and genomics ·(unknown), Lixin Rui	48
8	PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells 2019 ·Leukemia ·Fen Zhu, Hui Guo, Paul D. Bates, Shanxiang Zhang, Hui Zhang, Krystle Nomie, Yangguang Li, Li Lü, (unknown), Fangyu Wang, (unknown), (unknown), Nguyet M. Hoang, David T. Yang, Wei Xu, Liang Zhang, Michael Wang, Christian M. Capitini, Lixin Rui	54
9	Recent BCR stimulation induces a negative autoregulatory loop via FBXO10 mediated degradation of HGAL 2019 ·Leukemia ·Fengjie Guo, Yuan Luo, Xiaoyu Jiang, (unknown), Domenico Roberti, (unknown), Kranthi Kunkalla, Marco Magistri, Lixin Rui, Ramiro E. Verdún, Francisco Vega, Vincent T. Moy, Izidore S. Lossos	12
10	Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma 2018 ·Proceedings of the National Academy of Sciences ·Li Lü, Fen Zhu, Meili Zhang, Yangguang Li, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Fangyu Wang, Thomas A. Waldmann, Lixin Rui	69
11	Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma 2017 ·Journal of Biological Chemistry ·(unknown), (unknown), Stephanie Markovina, Natalie S. Callander, (unknown), Shelly M. Wuerzberger‐Davis, (unknown), John A. Kink, Peiman Hematti, Chelsea Hope, Fotis Asimakopoulos, Lixin Rui, Shigeki Miyamoto	35
12	Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies 2016 ·European Journal of Nuclear Medicine and Molecular Imaging ·Christopher G. England, Lixin Rui, Weibo Cai	19
13	Ratios of Four STAT3 Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells 2015 ·PLoS ONE ·(unknown), Douglas S. Annis, Lixin Rui, Stéphane Esnault, Deane F. Mosher	14
14	Withaferin A disrupts ubiquitin-based NEMO reorganization induced by canonical NF-κB signaling 2014 ·Experimental Cell Research ·Shawn S. Jackson, (unknown), (unknown), Kreg Grindle, Shelly M. Wuerzberger‐Davis, (unknown), Kevin W. McCool, Lixin Rui, Shigeki Miyamoto	27
15	Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma 2013 ·Proceedings of the National Academy of Sciences ·Michael Chiorazzi, Lixin Rui, Yandan Yang, Michele Ceribelli, (unknown), Carine W. Maurer, Stella Maris Ranuncolo, Hong Zhao, Weihong Xu, Wing C. Chan, Elaine S. Jaffe, Randy D. Gascoyne, Elı́as Campo, Andreas Rosenwald, German Ott, Jan Delabie, Lisa M. Rimsza, Shai Shaham, Louis M. Staudt	51
16	Malignant pirates of the immune system 2011 ·Nature Immunology ·Lixin Rui, Roland Schmitz, Michele Ceribelli, Louis M. Staudt	101
17	Tolerance Mechanisms in the Late Phase of the Antibody Response 2007 ·Advances in experimental medicine and biology ·Christopher C. Goodnow, James A. Campbell, Lixin Rui, Carola G. Vinuesa	6
18	ERK Signaling Is a Molecular Switch Integrating Opposing Inputs from B Cell Receptor and T Cell Cytokines to Control TLR4-Driven Plasma Cell Differentiation 2006 ·The Journal of Immunology ·Lixin Rui, James I. Healy, Julie Blasioli, Christopher C. Goodnow	66
19	Lymphoma and the Control of B Cell Growth and Differentiation 2006 ·Current Molecular Medicine ·Lixin Rui, Christopher C. Goodnow	26
20	A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity breakdown → 2005 ·Nature ·Carola G. Vinuesa, Matthew Cook, Constanza Angelucci, Vicki Athanasopoulos, Lixin Rui, (unknown), Di Yu, Heather Domaschenz, Belinda Whittle, Teresa Lambe, Ian S D Roberts, Richard R. Copley, John I. Bell, Richard J. Cornall, Christopher C. Goodnow	690

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact